Continuing at fiscal 2007 level
This article was originally published in The Tan Sheet
FDA and other federal agencies will operate under fiscal 2007 appropriation levels through Nov. 16, according to a continuing resolution passed by Congress on Sept. 27. With no fiscal 2008 appropriations approved by either chamber of Congress as the end of the federal fiscal year approached, House Appropriations Committee Chairman David Obey, D-Wis., on Sept. 25 introduced H. Res. 52 to continue funding government for six weeks. The spending directive for each federal agency would be replaced by its fiscal 2008 appropriation prior to Nov. 16 in the event Congress enacts the legislation before that date, according to H. Res. 52. Like other federal agencies not within the departments of Defense and Homeland Security, FDA's entire fiscal 2007 budget was included in a continuing resolution Congress enacted in February after failing to agree on fiscal 2008 spending levels in separate bills covering the traditional grouping of agencies (1"The Tan Sheet" Feb. 19, 2007, p. 14). House Appropriations Agriculture Subcommittee Chairwoman Rosa DeLauro, D-Conn., in March said the Bush administration's fiscal 2008 budget request for FDA did not reflect the agency's needs (2"The Tan Sheet" March 5. 2007, p. 18)...
You may also be interested in...
FDA 2007 Appropriations For Food, Drug Centers Outstrip Bush Request
FDA's Center for Drug Evaluation and Research and related activities are funded at $567.59 million for fiscal 2007 under the continuing resolution passed by Congress Feb. 14 and signed into law Feb. 15
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add a new product – Tibsovo, Servier’s treatment for IDH1-mutated acute myeloid leukemia and IDH1-mutated cholangiocarcinoma.
UK Aims To Quadruple Patient Recruitment To Industry Clinical Trials By 2027
The UK government has set aside dedicated funds to deliver ambitious changes that would make it quicker and easier for companies to trial more of their products in the National Health Service.